证券代码：832982 证券简称：锦波生物 公告编号：2024-048 山西锦波生物医药股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 投资者关系活动类别 □特定对象调研 □业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 √其他 （山西辖区上市公司 2024年投资者网上集体接待日暨年报业绩说明 会） ...

证券代码：832982 证券简称：锦波生物 公告编号：2024-047 山西锦波生物医药股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 投资者关系活动类别 √特定对象调研 □业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 二、 投资者关系活动情况 ...

证券代码：832982 证券简称：锦波生物 公告编号：2024-047 山西锦波生物医药股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 投资者关系活动类别 √特定对象调研 □业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 二、 投资者关系活动情况 ...

| 日期 | 代码 | 简称 | 成交价 | 成交数量（股） | 买入营业部 | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2024-05- | 832982 | 锦波生物 | 125.69 | 25000 | 平安证券股份有限公 | 中信证券股份有限公 | | 15 | | | | | 司北京分公司 | 司山西分公司 | ...

山西锦波生物医药股份有限公司 关于参加山西辖区上市公司 2024 年投资者 网上集体接待日暨年报业绩说明会的预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 说明会类型 为进一步加强与投资者的互动交流，山西锦波生物医药股份有限公司（以下 简称"公司"）将参加由山西证监局、山西省上市公司协会与深圳市全景网络有 限公司联合举办的"山西辖区上市公司 2024 年投资者网上集体接待日暨年报业 绩说明会"。 证券代码：832982 证券简称：锦波生物 公告编号：2024-045 二、 说明会召开的时间、地点 （一）会议召开时间：2024 年 5 月 20 日（周一）15:00-17:00。 （二）会议召开地点 三、 参加人员 联系人：孟宏钢 联系电话：0351-7779886 电子邮箱：sxjbsw001@163.com 公司董事长：杨霞女士； 特此公告。 公司董事、副总经理、董事会秘书：唐梦华女士； 公司副总经理、财务总监：薛芳琴女士。 四、 投资者参加方式 本次活动采用网络方式召开。 投资者可登 ...

Investment Rating - The report maintains a "Buy" rating for the company [5][4]. Core Views - The company is experiencing a rapid expansion of its self-branded products, particularly the medical dressing products, which is expected to drive sales [3]. - The core products are in a penetration phase, and new products are anticipated to enhance clinical usage options, with collaborations expected to expand commercialization pathways [4]. - The company reported a significant increase in revenue and net profit for Q1 2024, with revenue reaching 230 million yuan, a year-on-year growth of 76%, and net profit of 101 million yuan, a year-on-year increase of 136% [15][16]. Financial Summary - The company’s total revenue for 2023 was 780 million yuan, with projections of 1.21 billion yuan for 2024, 1.59 billion yuan for 2025, and 2.06 billion yuan for 2026 [9]. - The gross profit margin for Q1 2024 was 92%, reflecting a 2 percentage point increase year-on-year [16]. - The net profit margin for Q1 2024 reached 45%, an increase of 11.4 percentage points year-on-year [16]. Research and Development - The company has a rich pipeline of research projects, including recombinant collagen products that have entered clinical stages, which are expected to support future growth [17].

| 2024-05- 13 | 832982 | 锦波生物 | 121.8 | 25000 | 司北京金融大街证券 | 中信证券股份有限公 | | --- | --- | --- | --- | --- | --- | --- | | 日期 | 代码 | 简称 | 成交价 | 成交数量（股） | 买入营业部 招商证券股份有限公 营业部 | 卖出营业部 司山西分公司 | ...

| 日期 | 代码 | 简称 | 成交价 | 成交数量（股） | 买入营业部 | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2024-05- 09 | 835368 | 连城数控 | 20.68 | 143000 | 中信证券股份有限公 司大连分公司 | 长江证券股份有限公 司枝江公园路证券营 | | | | | | | | 业部 | | 2024-05- | 832982 | 锦波生物 | 126 | 33000 | 中信证券股份有限公 | 中信证券股份有限公 | | 09 | | | | | 司山西分公司 | 司山西分公司 | ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating that the stock price is expected to outperform the benchmark index by over 20% within the next six months [25]. Core Views - The company is projected to achieve revenues of 1.231 billion, 1.635 billion, and 2.073 billion yuan for the years 2023, 2024, and 2025, respectively, representing year-on-year growth rates of +57.71%, +32.87%, and +26.77% [7][8]. - The net profit attributable to the parent company is expected to be 493 million, 668 million, and 855 million yuan for the same years, with year-on-year growth rates of +64.42%, +35.46%, and +28.06% [7][8]. - The earnings per share (EPS) are forecasted to be 7.24, 9.81, and 12.56 yuan, with corresponding price-to-earnings (PE) ratios of 31, 23, and 18 times [7][8]. Financial Performance - In Q1 2024, the company reported a revenue of 226 million yuan, a year-on-year increase of +76.09%, and a net profit of 101 million yuan, up +135.72% year-on-year [15]. - The gross margin for Q1 2024 reached 91.90%, an increase of 1.96 percentage points year-on-year, while the net margin was 44.95%, up 11.47 percentage points year-on-year [16]. - The company's medical device segment achieved revenue of 680 million yuan in 2023, reflecting a year-on-year growth of +122.66% [16]. Strategic Developments - The company is actively expanding its collagen protein raw materials internationally and has established a strategic partnership with L'Oréal, marking a significant milestone in entering the supply chain of an internationally recognized brand [17]. - The company's core business focuses on various terminal medical device products and functional skincare products based on type A recombinant human collagen, with applications across multiple medical fields [17].

Investment Rating - The report maintains a "Buy" rating for the company [14] Core Views - The company achieved a revenue of 780 million yuan in 2023, representing a year-on-year growth of 99.97%, and a net profit attributable to shareholders of 300 million yuan, up 174.60% year-on-year [7][4] - The company is leading in the collagen market, with significant growth in its medical device segment and strong performance in its collagen products [7] - The company has a robust pipeline of research and development projects, focusing on recombinant collagen products, and aims to strengthen its brand "Wei Yi Mei" [7] Financial Summary - Revenue projections for 2024-2026 are adjusted to 1.25 billion yuan, 1.66 billion yuan, and 2.10 billion yuan respectively, with net profit forecasts of 496 million yuan, 667 million yuan, and 884 million yuan [7] - The gross margin is expected to improve from 90.2% in 2023 to 93.8% by 2026, while the return on equity (ROE) is projected to remain strong at around 33.1% by 2026 [4][7] - Earnings per share (EPS) are forecasted to be 5.61 yuan, 7.54 yuan, and 9.99 yuan for the years 2024, 2025, and 2026 respectively [7][4]